Bioaccelerate Portfolio Company Enhance Biotech Announces Closing of Merger with Ardent Pharmaceuticals
21. Dezember 2004 11:51 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Dec. 21, 2004 (PRIMEZONE) -- Enhance Biotech, Inc. (Pink Sheets:EBOI), a specialty pharmaceutical company developing a portfolio of products focused on lifestyle drugs, and Ardent...
Bioaccelerate's Development Partner AustCancer Commences Phase II Clinical Study of RP101 for Metastatic Pancreatic Cancer
15. Dezember 2004 08:05 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Dec. 15, 2004 (PRIMEZONE) -- Bioaccelerate's (OTCBB:BACL) development partner Australian Cancer Technology ("AustCancer" ASX:ACU) today said it has initiated a Phase II clinical study of...
Bioaccelerate to Co-Develop Anti-Cancer Portfolio of Five Clinical and Three Pre-Clinical Products with Faustus Forschung Cie., Translational Cancer Research GmbH and Faustus Forschung Translational Drug Development AG, Vienna, Austria
14. Dezember 2004 10:06 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Dec. 14, 2004 (PRIMEZONE) -- Bioaccelerate Holdings Inc. New York (OTCBB:BACL) and Faustus Forschungs Cie. Translational Cancer Research GmbH and Faustus Forschung Translational Drug...
Bioaccelerate Inc. and Supratek Pharma Inc. Announce License and Co-Marketing Agreement
19. November 2004 08:57 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK and MONTREAL, Nov. 19, 2004 (PRIMEZONE) -- Bioaccelerate Inc. (OTCBB:BACL) and Supratek Pharma Inc. today announced the formation of a strategic alliance to develop and commercialise one of...
Bioaccelerate Portfolio Company Enhance Biotech's New Merger Partner Ardent Pharmaceuticals Announces License Agreement with ALZA Corporation for Pain Compound
03. November 2004 13:33 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Nov. 3, 2004 (PRIMEZONE) -- Bioaccelerate (OTCBB:BACL) portfolio company Enhance Biotech, Inc. (Pink Sheets:EBOI), a developer of a portfolio of products focused on lifestyle drugs,...
Bioaccelerate Portfolio Company, Innovate Oncology Inc, Announces Closing Of Acquisition
18. Oktober 2004 08:13 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Oct. 18, 2004 (PRIMEZONE) -- Innovate Oncology Inc. (OTCBB:IOVO), a Nevada corporation, today announced that it has closed the acquisition of Innovate Oncology Inc., a Delaware corporation...
Bioaccelerate's CNSThera Enters Into Co-Development & License Agreement With DMI Biosciences Inc, for the Development of CNST 0004, for the Treatment of Multiple Sclerosis
11. Oktober 2004 09:15 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Oct. 11, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL), a pharmaceutical development organization, today announced that one of its portfolio companies, CNSThera, a developer...
Bioaccelerate to Invest in Australian Cancer Technology
07. Oktober 2004 11:13 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Oct. 7, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL), a pharmaceutical development organization, today announced that it will invest in Australian Cancer Technology...
Bioaccelerate Appoints Bruce Murdoch as Head of Bioaccelerate's Anti-Infective Division
06. Oktober 2004 10:18 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Oct. 6, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL), a pharmaceutical development organization, today announced that it has appointed Bruce Murdoch as Head of its...
Bioaccelerate Portfolio Company Announces The Following: Enhance's LI301 for Premature Ejaculation Announces Recruitment of Patients for Dose Ranging Study Prior to Commencement of Phase III Trial Next Year
01. Oktober 2004 13:19 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Oct. 1, 2004 (PRIMEZONE) -- Enhance Biotech (EBOI) is announcing the commencement of recruitment this week of a definitive dose-ranging trial in preparation for Phase III of its premature...